What Treatments Are Available for Wet Macular Degeneration?
In wet (neovascular/exudative) age-related macular degeneration (AMD), abnormal blood vessels develop under the macula and break, bleed, and leak fluid. This damages the macula and, if left untreated, can result in rapid and severe loss of central vision. The most effective treatments to date for wet AMD are several anti-angiogenic drugs.
Angiogenesis is a term used to describe the growth of new blood vessels and plays a crucial role in the normal development of body organs and tissue. Sometimes, however, excessive and abnormal blood vessel development can occur in diseases such as cancer (tumor growth) and AMD (retinal and macular bleeding).
Substances that stop the growth of these excessive blood vessels are called anti-angiogenic (anti = against; angio = vessel; genic = development), and anti-neovascular (anti = against; neo = new; vascular = blood vessels).
The focus of current anti-angiogenic drug treatments for wet AMD is to reduce the level of a particular protein called vascular endothelial growth factor, or VEGF, that stimulates abnormal blood vessel growth in the retina and macula; thus, these drugs are classified as anti-VEGF treatments.
Lucentis, Avastin, and Eylea
At present, these drugs are administered by injection directly into the eye after the surface has been numbed. The needle is very small and is inserted near the corner of the eye — not the center. During the injection procedure, the doctor will ask the patient to look in the opposite direction to expose the injection site, which also allows the patient to avoid seeing the needle. Anti-angiogenic drugs currently in use include Lucentis, Avastin, and Eylea. An earlier drug, Macugen, is also used in certain circumstances.
Deanne Jackson: From Despair to Hope with Wet Macular Degeneration
Deanne Jackson was "emotionally devastated" after receiving a diagnosis of macular degeneration, believing that her independent life was over. "When I got home after I'd heard the news that I had wet macular degeneration in my left eye with 20/400 vision, it was like an overnight devastation. I thought my life was over, because I am very independent. I take care of myself and my family."
The VisionAware Getting Started Kit can give you more ideas about how to live well with low vision. You can also sign up with VisionAware to receive free weekly email alerts with helpful information and tips for everyday living with vision loss.
Clinical Trials for Wet Macular Degeneration
In order to receive approval from the U.S. Food and Drug Administration (FDA), a new drug or treatment must be proven to be both safe and effective by undergoing a rigorous series of controlled unbiased studies. To prevent bias, neither the patient nor the examiners can know which patients received the actual treatment and which were the untreated (or "control") subjects.
These are called "double blind" or "double masked" studies and usually yield the most reliable results. The medication is coded and patients are placed at random into either the treatment or control group. When the study is concluded, the code is revealed and it is then possible to determine who received the actual drug and who received the inactive substance, or placebo.
As defined by the U.S. National Institutes of Health, most clinical trials are designated as Phase I, II, or III, based on the questions the study is seeking to answer:
- In Phase I clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe and effective dosage range, and identify possible side effects.
- In Phase II clinical trials, the study drug or treatment is given to a larger group of people (100-300) to determine if it is effective and to further evaluate its safety.
- In Phase III studies, the study drug or treatment is given to even larger groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
- In Phase IV studies, after the Food and Drug Administration has approved the drug, continuing studies will determine additional information, such as the drug's risks, side effects, benefits, and optimal use.
To learn more about clinical research on treatments for macular degeneration, you can visit the following resources:
- Clinical trial research on the VisionAware blog
- Macular degeneration research on the VisionAware blog
- The National Eye Institute website for information on clinical studies.
- The FDA has approved the Implantable Miniature Telescope (IMT) for end-stage AMD
- ClinicalTrials.gov provides a searchable list of all current clinical trials related to AMD.
- Macular Degeneration Partnership provides information on clinical trials for wet AMD, dry AMD, and a list of frequently asked questions about clinical trials.
Other Treatments for Wet AMD
Photodynamic therapy (PDT) was developed by researchers at the Massachusetts Eye and Ear Infirmary and has been approved for AMD treatment by the FDA since April 2000. PDT works as follows: A 10-minute intravenous administration of Visudyne (a light-sensitive drug) is followed by the application of a low-dose, non-thermal (light only) laser to the affected area of the retina. The drug circulates throughout the body's blood vessels, and is particularly attracted to new blood vessels, including the abnormal vessels under the macula.
The laser activates the drug, which selectively seals off the leaking blood vessels without damaging the surrounding healthy retinal tissue. This feature allows PDT to be used directly beneath the center of the macula, unlike thermal (heat) laser photocoagulation, which can burn and destroy normal retinal tissue.
Thermal Laser Photocoagulation
Thermal laser photocoagulation is a technique used by retinal surgeons to treat a number of eye conditions, one of which is wet AMD. A thermal (heat) laser is directed into the eye at abnormal blood vessels growing beneath the retina. The heat from the laser closes off the unwanted blood vessels, preventing further leakage and vision loss.
Thermal laser photocoagulation does not restore lost vision; therefore, in the past, it was critical that treatment be initiated as early as possible in the course of the disease. Unlike PDT, however, thermal laser can also destroy surrounding healthy retinal tissue as it seals the leakage from abnormal blood vessel growth; therefore, it is not used on vessels directly under the center of the macula. At present, thermal laser is rarely used in clinical practice.
Macular Translocation Surgery
Macular translocation is a surgery that involves detaching the retina from its base, rotating it slightly, and replacing it in a different position, so that the macula sits on a new, healthy base. While macular translocation surgery is unlikely to become standard treatment for everyone with wet AMD, it has proven effective for some people when done promptly. It does not work for dry AMD because, for reasons not yet understood, the degeneration recurs in the new position.
Have an Eye Examination
If you have not had an eye exam by an ophthalmologist in three or more years, you may qualify for help from the AMD Eye Care Program, offered through the American Academy of Ophthalmology. The program provides free eye exams for individuals who have not been diagnosed with AMD, are age 65 and older, are U.S. citizens or legal residents, and do not belong to an HMO or the Veterans' Administration (VA). Call the toll-free helpline at 1-866-324-EYES (3937) for more information.
- Author Ed Henkler Helps Readers Support Parents with Age-related Vision Loss
Ed Henkler, son of a mother with age-related macular degeneration, writes an e-book for helping families with useful tips and resources on dealing with vision loss. Read about his journey and his book.
- Updates from the London Project to Cure Blindness: Stem Cell Research for Wet and Dry Macular Degeneration
by Maureen Duffy on 8/22/2016
- A New, Innovative Potential Drug Therapy in Clinical Trials for the Treatment of Wet Macular Degeneration
by Maureen Duffy on 7/5/2016